Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors

[1]  E. Karapanagiotou,et al.  Heat shock protein inhibitors and vaccines as new agents in cancer treatment. , 2009, Expert opinion on investigational drugs.

[2]  S. Larson,et al.  Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer , 2007, Clinical Cancer Research.

[3]  D. V. Von Hoff,et al.  Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Solit,et al.  Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. , 2006, Current opinion in investigational drugs.

[5]  Hong Zhang,et al.  Identification of new biomarkers for clinical trials of Hsp90 inhibitors , 2006, Molecular Cancer Therapeutics.

[6]  S. Lakhani,et al.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Zuhowski,et al.  Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers , 2005, Clinical Cancer Research.

[8]  L. Grochow,et al.  Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Rose,et al.  Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. , 2005, The oncologist.

[10]  J. Sloan,et al.  Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Shapiro,et al.  Cardiac safety of liposomal anthracyclines. , 2004, Seminars in oncology.

[12]  F. Martin,et al.  Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. , 2004, Seminars in oncology.

[13]  S. Andrew,et al.  Hsp70 release from peripheral blood mononuclear cells. , 2004, Biochemical and biophysical research communications.

[14]  M. Soloff,et al.  Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin‐like growth factor binding protein‐2 , 2004, International journal of urology : official journal of the Japanese Urological Association.

[15]  Hong Zhang,et al.  Targeting multiple signal transduction pathways through inhibition of Hsp90 , 2004, Journal of Molecular Medicine.

[16]  G. Viale,et al.  Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. , 2004, Anticancer research.

[17]  David Zeltser,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[18]  M. Grever,et al.  Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent , 2004, Cancer Chemotherapy and Pharmacology.

[19]  J. Schellens,et al.  Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma , 2004, Cancer Chemotherapy and Pharmacology.

[20]  L. Neckers,et al.  Heat shock protein 90 , 2003, Current opinion in oncology.

[21]  P. Workman,et al.  The clinical applications of heat shock protein inhibitors in cancer - present and future. , 2003, Current cancer drug targets.

[22]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[23]  A. Brown,et al.  Role of the Cytosolic Chaperones Hsp70 and Hsp90 in Maturation of the Cardiac Potassium Channel hERG , 2003, Circulation research.

[24]  F. Dosio,et al.  From Conventional to Stealth Liposomes a new Frontier in Cancer Chemotherapy , 2003, Tumori.

[25]  A. Stromberg,et al.  Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. , 2003, Cancer detection and prevention.

[26]  C. Takimoto,et al.  Heat shock protein and proteasome targeting agents. , 2002, Hematology/oncology clinics of North America.

[27]  P. Workman,et al.  HSP90 as a new therapeutic target for cancer therapy: the story unfolds , 2002, Expert opinion on biological therapy.

[28]  D. Berry,et al.  Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  E. Sausville,et al.  Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Re , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Jason C. Young,et al.  Hsp90: a specialized but essential protein-folding tool. , 2001, The Journal of cell biology.

[31]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[32]  T G Myers,et al.  DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. , 1999, Journal of the National Cancer Institute.

[33]  P. Maxwell,et al.  Changes in the secretion of insulin-like growth factor binding proteins -2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines. , 1999, Cancer letters.

[34]  M. Newman,et al.  Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice , 1999, Cancer Chemotherapy and Pharmacology.

[35]  L. Neckers,et al.  The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin , 1998, Cancer Chemotherapy and Pharmacology.

[36]  P. Contreras,et al.  Identification of insulin-like growth factor binding protein-2 as a biochemical surrogate marker for the in vivo effects of recombinant human insulin-like growth factor-1 in mice. , 1997, The Journal of pharmacology and experimental therapeutics.

[37]  F. Hartl,et al.  Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Janoff,et al.  Lipid-based formulations of amphotericin B. , 1995, The Journal of antimicrobial chemotherapy.

[39]  M. Newman,et al.  Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®) , 1994 .

[40]  M. Ferrarini,et al.  Unusual expression and localization of heat‐shock proteins in human tumor cells , 1992, International journal of cancer.

[41]  T. Allen,et al.  Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.